Notify me when SPHERA FUNDS MANAGEMENT LTD. files a new 13F portfolio report.
⭐ Subscribe ⭐| Quarter | Holdings | Value $ | Bought | Sold | Net | Top Holdings | Form Type | Filing Time |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | 94 | $478,526,837 | +$153,350,966 | -$177,788,975 | -$24,438,009 | TEVA, BIIB, MLYS, SNDX, NVMI | 13F-HR | 17 Feb 2026, 15:50 |
| Q3 2025 | 101 | $421,601,350 | +$108,871,975 | -$168,240,287 | -$59,368,312 | TEVA, NICE, TSEM, NVMI, QQQ | 13F-HR | 14 Nov 2025, 15:30 |
| Q2 2025 | 101 | $382,494,339 | +$79,789,946 | -$119,881,829 | -$40,091,883 | TEVA, NVMI, SNDX, TSEM, CYTK | 13F-HR | 14 Aug 2025, 15:33 |
| Q1 2025 | 112 | $405,494,734 | +$62,244,110 | -$120,981,367 | -$58,737,257 | TEVA, SNDX, SNY, NVMI, AZN | 13F-HR | 15 May 2025, 15:31 |
| Q4 2024 | 103 | $541,445,250 | +$102,210,595 | -$125,161,759 | -$22,951,164 | TEVA, BBIO, SNY, SNDX, AZN | 13F-HR | 14 Feb 2025, 14:33 |
| Q3 2024 | 108 | $609,626,048 | +$136,506,452 | -$135,620,566 | +$885,886 | TEVA, SNY, BBIO, SNDX, AMZN | 13F-HR | 14 Nov 2024, 15:15 |
| Q2 2024 | 110 | $610,444,755 | +$168,343,555 | -$125,750,185 | +$42,593,370 | BBIO, SNY, CYTK, AMZN, SNDX | 13F-HR | 14 Aug 2024, 15:36 |
| Q1 2024 | 93 | $617,058,534 | +$178,962,720 | -$174,614,066 | +$4,348,654 | TEVA, SNY, NICE, CYTK, SNDX | 13F-HR | 15 May 2024, 15:42 |
| Q4 2023 | 89 | $533,010,674 | +$155,301,580 | -$213,553,289 | -$58,251,709 | TEVA, SNY, CYTK, NVMI, SNDX | Restatement | 15 Feb 2024, 07:40 |
| Q3 2023 | 75 | $416,688,470 | +$80,786,992 | -$86,088,326 | -$5,301,334 | SNY, AZN, ENPHASE ENERGY INC, JNJ, MRK | 13F-HR | 14 Nov 2023, 15:54 |
| Q2 2023 | 76 | $466,565,999 | +$102,414,844 | -$120,794,825 | -$18,379,981 | SNY, AZN, JNJ, NICE, AMZN | 13F-HR | 14 Aug 2023, 15:45 |
| Q1 2023 | 75 | $461,907,917 | +$240,568,266 | -$86,204,377 | +$154,363,889 | SNY, NICE, AZN, JNJ, TEVA | 13F-HR | 15 May 2023, 16:14 |
| Q4 2022 | 58 | $318,106,014 | +$51,514,947 | -$359,481,544 | -$307,966,597 | AZN, SNY, JNJ, SNDX, MRK | 13F-HR | 14 Feb 2023, 15:36 |
| Q3 2022 | 65 | $564,651,000 | +$200,517,253 | -$156,031,242 | +$44,486,011 | AZN, LLY, SNY, JNJ, MRK | 13F-HR | 14 Nov 2022, 16:20 |
| Q2 2022 | 50 | $526,869,000 | +$140,678,784 | -$170,213,277 | -$29,534,493 | AZN, JNJ, LLY, SNY, ABBV | 13F-HR | 15 Aug 2022, 15:32 |
| Q1 2022 | 59 | $596,537,000 | +$150,877,367 | -$361,306,070 | -$210,428,703 | AZN, JNJ, SNY, ABBV, PFE | 13F-HR | 16 May 2022, 15:34 |
| Q4 2021 | 85 | $841,966,000 | +$217,720,860 | -$403,086,219 | -$185,365,359 | ABBV, AZN, SNY, LLY, MRK | 13F-HR | 14 Feb 2022, 15:24 |
| Q3 2021 | 107 | $1,009,414,000 | +$350,705,947 | -$350,470,479 | +$235,468 | LLY, AZN, ABBV, PFE, SNY | 13F-HR | 15 Nov 2021, 15:41 |
| Q2 2021 | 121 | $1,050,881,000 | +$258,958,522 | -$356,104,738 | -$97,146,216 | AZN, JNJ, MRK, SNY, GNRC | 13F-HR | 16 Aug 2021, 18:15 |
| Q1 2021 | 158 | $1,088,325,000 | +$463,176,750 | -$305,454,835 | +$157,721,915 | LLY, JNJ, ABBV, MRK, SNY | 13F-HR | 17 May 2021, 06:01 |
| Q4 2020 | 104 | $962,608,000 | +$386,231,629 | -$406,377,574 | -$20,145,945 | LLY, MRK, JNJ, NVS, BMY | 13F-HR | 16 Feb 2021, 06:29 |
| Q3 2020 | 89 | $863,822,000 | +$254,953,398 | -$267,295,297 | -$12,341,899 | MRK, ABBV, JNJ, SNY, AZN | 13F-HR | 12 Nov 2020, 06:59 |
| Q2 2020 | 80 | $840,031,000 | +$343,530,320 | -$211,059,793 | +$132,470,527 | ABBV, MRK, SNY, AZN, JNJ | 13F-HR | 13 Aug 2020, 06:02 |
| Q1 2020 | 75 | $603,710,000 | +$200,247,940 | -$257,593,775 | -$57,345,835 | MRK, JNJ, BMY, SNY, NVO | 13F-HR | 14 May 2020, 07:49 |
| Q4 2019 | 81 | $753,601,000 | +$218,301,558 | -$250,748,163 | -$32,446,605 | JNJ, BMY, SNY, MRK, NVO | 13F-HR | 13 Feb 2020, 12:11 |
| Q3 2019 | 79 | $647,318,000 | +$242,211,113 | -$202,387,202 | +$39,823,911 | BMY, JNJ, GILD, MRK, SNY | 13F-HR | 14 Nov 2019, 06:01 |
| Q2 2019 | 84 | $660,023,000 | +$181,302,341 | -$231,433,665 | -$50,131,324 | JNJ, ALXN, BMY, MRK, AZN | 13F-HR | 14 Aug 2019, 06:02 |
| Q1 2019 | 2 | $0 | $0 | $0 | $0 | New Holdings | 20 Jun 2019, 07:37 | |
| Q1 2019 | 98 | $723,860,000 | +$232,611,595 | -$214,754,186 | +$17,857,409 | BMY, JNJ, FOLD, ALXN, MRK | 13F-HR | 15 May 2019, 06:23 |
| Q4 2018 | 98 | $550,946,000 | +$183,625,326 | -$220,130,849 | -$36,505,523 | MYL, MRK, BMY, CELG, FOLD | 13F-HR | 14 Feb 2019, 06:42 |
| Q3 2018 | 111 | $763,922,000 | +$290,599,318 | -$179,865,564 | +$110,733,754 | MRK, MYL, JNJ, GSK, BMY | 13F-HR | 14 Nov 2018, 12:39 |
| Q2 2018 | 107 | $619,205,000 | +$230,326,589 | -$232,044,018 | -$1,717,429 | MRK, MYL, GSK, GILD, SHPG | 13F-HR | 13 Aug 2018, 08:30 |
| Q1 2018 | 104 | $572,806,000 | +$188,169,571 | -$231,811,230 | -$43,641,659 | MRK, SHPG, CELG, FOLD, MYL | 13F-HR | 10 May 2018, 08:44 |
| Q4 2017 | 130 | $617,863,000 | +$200,673,256 | -$131,655,527 | +$69,017,729 | CELG, MYL, MRK, BIIB, SRPT | 13F-HR | 12 Feb 2018, 14:44 |
| Q3 2017 | 121 | $551,350,000 | +$144,872,553 | -$118,206,574 | +$26,665,979 | CELG, BIIB, MRK, GILD, GSK | Restatement | 27 Nov 2017, 10:57 |
| Q2 2017 | 119 | $475,700,000 | +$166,874,812 | -$83,200,609 | +$83,674,203 | CELG, BIIB, MRK, GSK, GILD | 13F-HR | 09 Aug 2017, 10:08 |
| Q1 2017 | 104 | $372,528,000 | +$146,243,609 | -$112,320,852 | +$33,922,757 | CELG, BIIB, NVS, MRK, SRPT | 13F-HR | 11 May 2017, 06:08 |
| Q4 2016 | 98 | $320,509,000 | +$80,280,149 | -$180,154,206 | -$99,874,057 | MRK, CELG, TEVA, ALXN, CLCD | 13F-HR | 13 Feb 2017, 08:44 |
| Q3 2016 | 101 | $434,432,000 | +$136,615,637 | -$74,676,932 | +$61,938,705 | MRK, TEVA, SRPT, AGN, LLY | 13F-HR | 14 Nov 2016, 07:46 |
| Q2 2016 | 83 | $328,927,000 | +$121,067,702 | -$142,534,518 | -$21,466,816 | TEVA, AGN, GILD, LLY, CELG | 13F-HR | 10 Aug 2016, 10:17 |
| Q1 2016 | 82 | $354,734,000 | +$90,094,055 | -$176,285,366 | -$86,191,311 | PFE, TEVA, BIIB, AGN, GILD | 13F-HR | 16 May 2016, 06:17 |
| Q4 2015 | 112 | $510,029,000 | +$138,397,859 | -$168,200,902 | -$29,803,043 | TEVA, PFE, BIIB, AGN, ABBV | 13F-HR | 11 Feb 2016, 09:46 |
| Q3 2015 | 118 | $498,835,000 | +$151,533,878 | -$201,657,807 | -$50,123,929 | AGN, TEVA, BIIB, PFE, ABBV | 13F-HR | 16 Nov 2015, 06:05 |
| Q2 2015 | 121 | $643,576,000 | +$230,284,233 | -$295,276,803 | -$64,992,570 | AGN, GILD, PFE, ABBV, BIIB | 13F-HR | 06 Aug 2015, 13:19 |
| Q1 2015 | 136 | $679,394,000 | +$322,205,288 | -$230,432,098 | +$91,773,190 | B108PS, PFE, GILD, TEVA, ABBV | 13F-HR | 11 May 2015, 06:43 |
| Q4 2014 | 117 | $527,939,000 | +$167,990,370 | -$281,872,644 | -$113,882,274 | NVS, B108PS, PFE, TEVA, SLXP | 13F-HR | 12 Feb 2015, 12:42 |
| Q3 2014 | 117 | $593,510,000 | +$305,256,956 | -$97,254,629 | +$208,002,327 | NVS, PFE, TEVA, B108PS, MRK | Restatement | 20 Nov 2014, 07:33 |
| Q2 2014 | 86 | $369,242,000 | +$144,675,799 | -$167,151,347 | -$22,475,548 | NVS, MRK, TEVA, JNJ, PFE | Restatement | 20 Aug 2014, 06:03 |
| Q1 2014 | 99 | $390,672,000 | +$196,263,958 | -$94,394,983 | +$101,868,975 | NVS, GSK, MRK, PFE, JNJ | 13F-HR | 14 May 2014, 12:02 |
| Q4 2013 | 87 | $277,569,000 | $0 | $0 | $0 | GSK, PFE, XLF, MRK, SHPG | 13F-HR | 13 Feb 2014, 14:03 |